1. The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model 
Alasdair P. MacGowan, Karen E. Bowker, Mandy Wootton, H. Alan Holt 
Clinical Microbiology and Infection 
Volume 5, Issue 4, Pages (April 1999)
DOI: /j tb00123.x
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Bactericidal effect of moxifloxacin, simulation dose of 400 mg every 24 h on H. influenzae: (a) strain NCTC 11931, β-lactamase negative, moxifloxacin MIC 0.06 mg/L; (b) strain 4718, β-lactamase positive, moxifloxacin MIC 0.06 mg/L; (c) strain 4797, cefuroxime resistant, moxifloxacin MIC 0.06 mg/L, and mutant strain 4797M, MIC 1.0 mg/L; (d) strain 5100, imipenem resistant, moxifloxacin MIC 0.06 mg/L and mutant strain 5100M, MIC 0.5 mg/L.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00123.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Bactericidal effect of moxifloxacin, simulated dose of 400 mg every 24 h on M. catarrhalis: (a) strain 9567, β-lactamase negative, moxifloxacin MIC 0.08 mg/L, and mutant, MIC 1.0 mg/L; (b) strain 9573, β-lactamase positive, moxifloxacin MIC 0.1 mg/L.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00123.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

4. Figure 3
Moxifloxacin antibacterial activity against H. influenzae and M. catarrhalis strains: relationship between AUBKC and AUC/MIC at 24 h and 48 h.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00123.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions